Predicting disease progression in progressive cerebellar ataxias: integrating clinical, imaging, fluid, genetic, and digital biomarkers

Hao Y and Hao X (2026) Predicting disease progression in progressive cerebellar ataxias: integrating clinical, imaging, fluid, genetic, and digital biomarkers. Front. Neurol. 17:1921210. doi: 10.3389/fneur.2026.1921210 

This review synthesizes evidence across five complementary biomarker domains, clinical, imaging, fluid, genetic, and digital, and judges their readiness for forecasting onset and progression. Clinical scales such as SARA capture genotype-specific trajectories but lose sensitivity at the extremes of the disease course. Volumetric, microstructural, and spectroscopic MRI and blood neurofilament light chain change before ataxia onset and predict subsequent decline, whereas repeat length and genetic modifiers set prior risk. Wearable-sensor gait and balance metrics detect change earlier than clinical scales and sharply reduce required sample sizes. We argue that no single modality satisfies every context of use, and that stage-specific, multimodal composites, integrated through harmonized international cohorts and machine learning, offer the most credible path to prognostic enrichment and to shorter, adequately powered, and preventive trials.

Evolution of Friedreich's Ataxia Management Across Established and Emerging Therapies-Systematic Review and Meta-Analysis

Garah B, Aljabri H, Aljohani A, Alnuzha E, Maihoub A, Almuzaini R, Aljohani L, Alshamani L, Alluqmani M. Evolution of Friedreich's Ataxia Management Across Established and Emerging Therapies-Systematic Review and Meta-Analysis. J Clin Med. 2026 Jul 21;15(14):5707. doi: 10.3390/jcm15145707. PMID: 42513621; PMCID: PMC13413417. 

 Friedreich’s ataxia (FRDA) is a challenging neurodegenerative disorder with limited pharmacologic treatment options. Among the therapies reviewed, omaveloxolone was the only agent to demonstrate a statistically significant improvement in neurological outcomes; however, this finding is based on very low-certainty evidence. Consequently, omaveloxolone may be the most promising current pharmacologic option, but its true efficacy remains uncertain and should be confirmed in larger, longer, and well-designed randomized controlled trials. Other pharmacologic agents showed no consistent evidence of benefit. Safety outcomes were broadly comparable between intervention and control groups; however, available safety evidence remains limited by imprecision, small sample sizes, and relatively short follow-up periods. Although no substantial increase in adverse events was observed, confidence in the safety estimates remains limited.